أعرض في EDS

Overcoming therapy failure in elderly patients with chronic myeloid leukemia

التفاصيل البيبلوغرافية
العنوان: Overcoming therapy failure in elderly patients with chronic myeloid leukemia
المؤلفون: Marta Medeot, Mario Tiribelli
المصدر: International Journal of Hematologic Oncology. 3:353-365
بيانات النشر: Future Medicine Ltd, 2014.
سنة النشر: 2014
مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.drug_class, business.industry, Ponatinib, Myeloid leukemia, Imatinib, Hematology, Tyrosine-kinase inhibitor, Dasatinib, chemistry.chemical_compound, Nilotinib, chemistry, hemic and lymphatic diseases, Internal medicine, Toxicity, Immunology, medicine, Pharmacology (medical), business, Bosutinib, medicine.drug
الوصف: SUMMARY Chronic myeloid leukemia (CML) affects mainly older adults, as median age at diagnosis is 60–65 years. For a long time, survival of elderly CML patients has been shorter compared with younger patients. With the advent of the first tyrosine kinase inhibitor (TKI), imatinib, long-term outcome has significantly improved, including in the elderly, with rates of cytogenetic and molecular responses roughly equal to those attained in the young, as well as manageable toxicity. More recently, second-generation (dasatinib, nilotinib and bosutinib) and third-generation (ponatinib) TKIs were employed in CML patients failing imatinib or other front-line treatments. Despite a shorter follow-up, these TKIs showed remarkable activity in elderly patients. This review focuses on the therapeutic strategies to prevent and overcome treatment failure in elderly CML patients.
تدمد: 2045-1407
2045-1393
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f39f218ff4014ac01e9bc88c8ec409a0
https://doi.org/10.2217/ijh.14.32
حقوق: OPEN
رقم الأكسشن: edsair.doi...........f39f218ff4014ac01e9bc88c8ec409a0
قاعدة البيانات: OpenAIRE
الوصف
تدمد:20451407
20451393